论文部分内容阅读
目的 探讨非何杰金淋巴瘤 (NHL)中 P1 6基因缺失情况及其与组织亚型和治疗的关系。方法 采用聚合酶链反应 -单链构象多态银染技术 (PCR- SSCP)检测 2 9例非何杰金淋巴瘤患者 P1 6基因的变化。结果 2 9例非何杰金淋巴瘤中 1 2例存在 P1 6基因缺失 ,总缺失率 41 .3% ;1 2例缺失中有 6例在两个疗程化疗后缺失消失 ;高度恶性淋巴瘤缺失率高。结论 P1 6基因缺失在 NHL发病中起一定作用 ,其发生率与组织亚型和治疗效果有关。
Objective To investigate the deletion of P16 gene in non-Hodgkin’s lymphoma (NHL) and its relationship with histological subtypes and treatment. Methods Polymerase chain reaction-single strand conformation polymorphism silver staining (PCR-SSCP) was used to detect the changes of P16 gene in 29 non-Hodgkin’s lymphoma patients. Results Among the 29 cases of non-Hodgkin’s lymphoma, there was a deletion of P16 gene in 12 cases, and the total deletion rate was 41.3%; 6 cases of deletions in 12 cases disappeared after two courses of chemotherapy; the loss of high-grade lymphoma was lost. The rate is high. Conclusion The deletion of P16 gene plays a role in the pathogenesis of NHL, and its incidence is related to histological subtypes and therapeutic effects.